ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: When compared to the conventional antibody evinacumab, C44-Fc fusion protein had similar ability of rescuing ANGPTL3-mediated suppression of LPL activity and the lipid-reducing effect as well as relieving function in NAFLD.